Effect of mannitol on acute kidney injury induced by cisplatin
| العنوان: | Effect of mannitol on acute kidney injury induced by cisplatin |
|---|---|
| المؤلفون: | Anne-Marie Bégin, Marie-Andrée Fournier, Nathalie Letarte, Jean-Philippe Adam, Emmie Lavallée, Marie-Lawrence Monfette, Vanessa Samouëlian, Miguel Chagnon, Étienne Boudrias-Dalle, Denis Soulières |
| المصدر: | Supportive Care in Cancer. 29:2083-2091 |
| بيانات النشر: | Springer Science and Business Media LLC, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Urinary system, Antineoplastic Agents, Gastroenterology, Nephrotoxicity, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Mannitol, 030212 general & internal medicine, Adverse effect, Aged, Retrospective Studies, Aged, 80 and over, Cisplatin, business.industry, Acute kidney injury, Cancer, Acute Kidney Injury, Middle Aged, medicine.disease, Diuretics, Osmotic, Oncology, 030220 oncology & carcinogenesis, Toxicity, Female, business, medicine.drug |
| الوصف: | Acute kidney injury (AKI) is a frequent dose-limiting toxicity induced by cisplatin. Mannitol has been used in hydration protocols to mitigate this adverse event but its role remains controversial. The aim of this study is to define the impact of mannitol on AKI in patients receiving cisplatin. This retrospective observational study was conducted in cancer patients who received at least one dose of cisplatin between September 2010 and December 2016 at the Centre hospitalier de l’Universite de Montreal. The primary outcome of this study was the comparison of all grade cisplatin-associated AKI between hydration protocols with or without mannitol. A total of 1821 patients were included of which 658 received mannitol whilst 1163 received hydration alone. The risk of all grade cisplatin-associated AKI was significantly lower for the mannitol group (Hazard Ratio (HR) = 0.62; 95% CI [0.42, 0.89]). This result was mainly driven by gynecologic (HR = 0.50), upper gastrointestinal (HR = 0.32), urinary tract malignancies (HR = 0.29) and lymphoma (HR = 0.33). No significant difference was seen for head and neck (HN), lung, germ cells and other cancers. However, HN cancers patients receiving mannitol had fewer grade 2 and 3 AKI. Significantly fewer AKI events were observed in HN, lung, upper gastrointestinal and urinary tract cancer when mannitol was added for cisplatin dose |
| تدمد: | 1433-7339 0941-4355 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24cf1ecb405547243beb7260d665f025Test https://doi.org/10.1007/s00520-020-05703-7Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....24cf1ecb405547243beb7260d665f025 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14337339 09414355 |
|---|